Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial

Loading news article.

Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial | WAPE

Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial

Article summary

Related companies

Comments —